could help speed treatments to patients. An important
outcome of this conference was the general acceptance
of a new measurement tool, EZ area. EZ area is an
outcome measure that will help researchers quickly
determine if an emerging therapy is saving vision
for people with RP in a clinical study. The EZ area
measure more closely correlates with vision changes
rather than having to rely on improvement in the
reading of lines on an eye chart.
Also in the issue is a Research Roundup on NACA, a
promising drug treatment for retinitis pigmentosa. The
Foundation’s Clinical Research Institute is investing
up to $7.5 million to advance this emerging drug
treatment into and through a Phase II clinical trial.
I invite you to also read the engaging profile of
Foundation CEO Bill Schmidt. Bill will end his tenure
as our CEO this spring — after 12 years at the helm.
His impact on the organization is immeasurable. We
will miss him but wish him the very best as he embarks
on his next professional challenge.
A second profile in the issue is that of longtime
volunteer Ken Rietz. Ken has had an amazing career as
a political strategist at the highest levels of our political
system, all while adapting to the vision limitations of
RP. His story is a good read.
Enjoy the issue. We are excited to be able to share
this significant research news with you. We are also
highly mindful that the research would not be possible
without the continuing support of our generous
donors. Thank you.
June 21–23, 2018
Sheraton San Diego Hotel and Marina
San Diego, California
Emerging Science • Social Events • City Excursions
Get Ready for
We are excited to bring our biennial meeting to San Diego —
wonderful weather and a myriad of family friendly activities!
Programming will focus on the latest research and treatment advances plus sessions
on thriving despite vision loss and numerous social and community-building opportunities.
Details will be announced in the coming months.
The National Conference of the Foundation Fighting Blindness!